Non-Tuberculous Mycobacterial Pneumonia Clinical Trial
Official title:
Open Label Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for a Single Adult With Non-Tuberculous Mycobacteria Infection
An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment regimen. In one subject, who had a reduction in sputum culture concentration of Bacterium bolletii from plus 3 to plus 1 corresponding to a 2-3 log10 cfu/gm reduction during the treatment, the one-week post treatment follow-up sputum culture had increased to plus 2. It is hypothesized that a longer treatment period may be necessary to fully eradicate NTM from the sputum culture in chronic lung disease. This study will extend the period of gNO exposure for a prolonged period of time (3 months) to attempt to fully eradicate the NTM in this single subject. This study will transition from the medical clinic to supervised delivery in the patient's home environment.
Primary Objective: Determine the efficacy of prolonged delivery of inhaled nitric oxide to
treat an adult patient with pulmonary NTM Primary Endpoint: Eradication of NTM growth in
sputum cultures. Efficacy will be assessed by the antimicrobial effect of inhaled NO on the
density of NTM species and other microorganisms in the sputum.
• as confirmed by measurement of semi-quantitative culture sputum growth which has been
verified with serial dilution technique on Day 7, 14, 21 and every 21 days thereafter for 90
days as compared to pre-treatment baseline sputum culture.
Secondary Objective(s): Determine the safety & efficacy of inhaled nitric oxide
Secondary Endpoint(s):
1. Safety
• as evaluated by the number of unanticipated adverse events during home delivery in
clinical labs (hematology, coagulation, and serum chemistries); in vitals; in inspired
concentration of NO, O2 and NO2 delivered to subject and; in methemoglobin and oxygen
saturation levels.
2. Efficacy
- as determined by improvement in lung function as measured by spirometry, endurance
as measured by six minute walk-test and quality of life as determined by
self-reporting quality of life questionnaire (CFQ-R) on Day 7, 14, 21 and every 21
days thereafter for 90 days as compared to pre-treatment baseline data.
- as assessed by recurrence of NTM in sputum as confirmed by measurement of
semi-quantitative culture sputum growth on Day 30 and 60 post treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Not yet recruiting |
NCT04600232 -
TB-LAM in the Diagnosis of TB
|
N/A | |
Recruiting |
NCT04538898 -
A Retrospective Study Investigating the Factors Related to Non-tuberculous Mycobacterial Pulmonary Disease in Hong Kong
|
||
Recruiting |
NCT06144996 -
Development of a Canadian Bronchiectasis and NTM Database
|
||
Completed |
NCT03794284 -
Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium
|
||
Completed |
NCT04685720 -
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
|
N/A | |
Completed |
NCT04079400 -
Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis
|
||
Recruiting |
NCT06413459 -
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
|
||
Not yet recruiting |
NCT03934034 -
A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
|
||
Recruiting |
NCT05376280 -
Nutritional Assessment in Non-tuberculous Mycobacteria Pulmonary Disease
|